REDUCTION OF LIPOPROTEIN(A) BY LDL-APHERESIS USING A DEXTRAN SULFATE CELLULOSE COLUMN IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引:39
|
作者
KOIZUMI, J
KOIZUMI, I
UNO, Y
INAZU, A
KAJINAMI, K
HARAKI, T
YAGI, K
KAMON, N
MIYAMOTO, S
TAKEGOSHI, T
MABUCHI, H
TAKEDA, R
TANI, N
TAKADA, S
机构
[1] HOKURIKU HOSP,DEPT INTERNAL MED,KANAZAWA 921,JAPAN
[2] FUKUI PREFECTURAL HOSP,DEPT INTERNAL MED,FUKUI 910,JAPAN
[3] KANEGAFUCHI CHEM IND,CENT RES LAB,KOBE,JAPAN
关键词
D O I
10.1016/0021-9150(93)90068-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipoprotein(a) (Lp(a)) was eliminated by LDL-apheresis using a dextran sulfate cellulose column in 3 homozygous and 10 heterozygous familial hypercholesterolemic patients. Immediately after LDL-apheresis by the LA- 1 5 system (continuous LDL apheresis), there were significant reductions in Lp(a) concentrations (28.6 +/- 11.8 mg/dl (mean +/- S.E.) to 9.6 +/- 5.6 mg/dl (P < 0.01)), and in LDL-cholesterol concentrations (156 +/- 32 mg/dl to 48 +/- 18 mg/dl (P < 0.01)). Immediately following LDL-apheresis, Lp(a) and LDL-cholesterol were reduced by 67.4% +/- 11.6% and 68.3% +/- 11.8%, respectively. The removal of Lp(a) paralleled that of LDL-cholesterol. The reduced levels of Lp(a) nearly returned to baseline within 7 days. In 6 of the heterozygous FH patients the rates of recovery of LDL cholesterol and Lp(a) were calculated, according to Apstein's equation after discontinuing lipid altering drug treatment for 4 weeks. Mean constant k values of LDL cholesterol and Lp(a) were 0.354 (range : 0.136-0.752) and 0.427 (range 0.112-0.933), respectively. The average concentration during the 7 days following LDL-apheresis was calculated. Average reductions were 28% in LDL cholesterol and 18% in Lp(a). Pravastatin treatment, which continued for 4 weeks, significantly decreased LDL cholesterol (P < 0.01); however, before LDL-apheresis pravastatin treatment significantly increased Lp(a) levels (P < 0.05) in a small number (n = 6) of the FH patients, who had been regularly treated with LDL-apheresis. These results suggest that LDL-apheresis using the dextran sulfate cellulose column is an effective treatment to reduce levels of serum Lp(a) and LDL proportionally. This therapy may be of value in the prevention and regression of coronary artery disease in FH patients.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 50 条
  • [41] Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia
    Dlouha, Dana
    Blaha, Milan
    Huckova, Pavlina
    Lanska, Vera
    Hubacek, Jaroslav Alois
    Blaha, Vladimir
    GENES, 2023, 14 (08)
  • [42] The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy
    Yamamoto, A
    Harada-Shiba, M
    Kawaguchi, A
    Oi, K
    Kubo, H
    Sakai, S
    Mikami, Y
    Imai, T
    Ito, T
    Kato, H
    Endo, M
    Sato, I
    Suzuki, Y
    Hori, H
    ATHEROSCLEROSIS, 2000, 153 (01) : 89 - 98
  • [43] LDL-APHERESIS SELECTIVELY INDUCES CHANGES IN THE LIPIDOME AND PROTEOME OF APO-AI-CONTAINING LIPOPROTEIN PARTICLES IN FAMILIAL HYPERCHOLESTEROLEMIA
    Orsoni, A.
    Guerin, M.
    Couturier, M.
    Dallinga-Thie, G. M.
    Levels, J. H. M.
    Saheb, S.
    Atassi-Dumont, M.
    Bonnefont-Rousselot, D.
    Kontush, A.
    Carrie, A.
    Bruckert, E.
    Chapman, M. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 76 - 76
  • [44] The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy
    Yamamoto, A
    Harada-Shiba, M
    Endo, M
    Kusakabe, N
    Tanioka, T
    Kato, H
    Shoji, T
    ATHEROSCLEROSIS, 2006, 186 (01) : 126 - 131
  • [45] LDL Apheresis Is Associated With a Reduction in Markers of Chronic Inflammation in Patients With Familial Hypercholesterolemia
    Lynch, Donald R.
    Winegar, Deborah A.
    Connelly, Margery
    Yancey, Patricia G.
    Pourfarzib, Ray
    Fazio, Sergio
    Linton, MacRae F.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [46] Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia
    Parhofer, KG
    Barrett, PHR
    Demant, T
    Richter, WO
    Schwandt, P
    JOURNAL OF LIPID RESEARCH, 1996, 37 (11) : 2383 - 2393
  • [47] Survival and cardiovascular disease in homozygotes and compound heterozygotes for familial hypercholesterolemia treated with LDL-apheresis
    Benlian, P
    deGennes, JL
    Dairou, F
    Assogba, U
    Turpin, G
    Bernard, C
    Bertrand, V
    Bereziat, G
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 42 - 42
  • [48] LDL-APHERESIS IN 2 PATIENTS WITH EXTREMELY ELEVATED LIPOPROTEIN(A) LEVELS
    BAMBAUER, R
    SCHIEL, R
    KELLER, HE
    LATZA, R
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1995, 18 (05): : 286 - 290
  • [49] REGRESSION OF ATHEROSCLEROSIS OCCURS EVEN IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA BY LOWERING CHOLESTEROL WITH LDL-APHERESIS
    YAMAMOTO, A
    KIKKAWA, T
    YOKOYAMA, S
    KISHINO, B
    HAYASHI, R
    KOGA, N
    SATANI, M
    ARTIFICIAL ORGANS, 1988, 12 (04) : 370 - 370
  • [50] REGRESSION OF CORONARY CALCIFICATION AND CAROTID ATHEROMAS IN FAMILIAL HOMOZYGOUS HYPERCHOLESTEROLEMIA VIA LDL-APHERESIS
    BRICKER, LA
    KOZLOVSKIS, PL
    ORFUSS, M
    CALDERON, M
    WALBURN, F
    AGATSTON, A
    VONALBERTINI, B
    LANE, DM
    CLINICAL RESEARCH, 1991, 39 (02): : A262 - A262